Blinatumomab: a new era of treatment for adult ALL?
Mené sur 189 patients atteints d'une leucémie lymphoblastique aiguë réfractaire ou récidivante, cet essai de phase II évalue l'efficacité, du point de vue de la rémission complète ou partielle, et la toxicité du blinatumomab
Standard chemotherapy for acute lymphoblastic leukaemia (ALL) is, at present, far from ideal. Although intensified cytotoxic therapy has improved the prognosis of children with ALL, this approach has provided little benefit in adults, despite the recent introduction of paediatric-inspired regimens for adults. Most patients respond to induction chemotherapy, but up to 50% experience relapse with chemoresistant disease. Persistence or reappearance of minimal residual disease (MRD) is the most important adverse prognostic factor.
The Lancet Oncology , commentaire, 2013